ArticleScientific reports2020
Preclinical validation of therapeutic targets predicted by tensor factorization on heterogeneous graphs.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Target identification and assessment in the era of AI.Nature reviews. Drug discovery · 2026Review
- Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation.Nature machine intelligence · 2026Article
- Integration of artificial intelligence and high-content screening enabled identification of drugs for long-term treatment of cerebral cavernous malformation disease.bioRxiv : the preprint server for biology · 2025Article
- The role of graph topology in the performance of biomedical Knowledge Graph Completion models.Bioinformatics (Oxford, England) · 2025Article
- Generative artificial intelligence based models optimization towards molecule design enhancement.Journal of cheminformatics · 2025Review
- Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer.Molecular cancer therapeutics · 2025Article
- Cross-modal embedding integrator for disease-gene/protein association prediction using a multi-head attention mechanism.Pharmacology research & perspectives · 2024Article
- Comprehensive applications of the artificial intelligence technology in new drug research and development.Health information science and systems · 2024Review
- Natural Language Processing for Drug Discovery Knowledge Graphs: Promises and Pitfalls.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Bridging the Worlds of Pharmacometrics and Machine Learning.Clinical pharmacokinetics · 2023Review
- Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis.Translational neurodegeneration · 2023Review
- A publication-wide association study (PWAS), historical language models to prioritise novel therapeutic drug targets.Scientific reports · 2023Article
- Review: A Roadmap to Use Nonstructured Data to Discover Multitarget Cancer Therapies.JCO clinical cancer informatics · 2023Review
- Hetnet connectivity search provides rapid insights into how two biomedical entities are related.bioRxiv : the preprint server for biology · 2023Article
- EMBL's European Bioinformatics Institute (EMBL-EBI) in 2022.Nucleic acids research · 2023Article
- Article
- Hetnet connectivity search provides rapid insights into how biomedical entities are related.GigaScience · 2022Article
- Ensembles of knowledge graph embedding models improve predictions for drug discovery.Briefings in bioinformatics · 2022Article
- Learning to discover medicines.International journal of data science and analytics · 2022Review
- Integrating and formatting biomedical data as pre-calculated knowledge graph embeddings in the Bioteque.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Incorrect drug target identification is a major obstacle in drug discovery. Only 15% of drugs advance from Phase II to approval, with ineffective targets accounting for over 50% of these failures
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.